Match!

Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now

Published on Sep 1, 2017in Vaccine3.269
· DOI :10.1016/j.vaccine.2017.08.006
Ashish A. Deshmukh8
Estimated H-index: 8
(UF: University of Florida),
Scott B. Cantor40
Estimated H-index: 40
+ 6 AuthorsJagpreet Chhatwal23
Estimated H-index: 23
(Harvard University)
Abstract
Abstract Importance Outcomes of treating high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, remain uncertain. Emerging evidence shows that post HSIL treatment adjuvant quadrivalent human papillomavirus (qHPV) vaccination improves the effectiveness of treatment. However, no recommendations exist regarding the use of qHPV vaccine as an adjuvant form of therapy. Our objective was to determine whether post-treatment adjuvant vaccination should be adopted in HIV-infected MSM (individuals at highest risk for anal cancer) on the basis of cost-effectiveness determined using existing evidence or whether future research is needed. Methods We developed a Markov (state-transition) cohort model to assess the cost-effectiveness of post-treatment adjuvant HPV vaccination of 27 years or older HIV-infected MSM. We first estimated cost-effectiveness and then performed value-of-information (VOI) analysis to determine whether future research is required by estimating the expected value of perfect information (EVPI). We also estimated expected value of partial perfect information (EVPPI) to determine what new evidences should have highest priority. Results With the incremental cost-effectiveness ratio (ICER) of 71,937/QALY, “treatment plus vaccination” was the most cost-effective HSIL management strategy using the willingness-to-pay threshold of 100,000/QALY. We found that population-level EVPI for conducting future clinical research evaluating HSIL management approaches was US2 million (range 6–0 million). The EVPPI associated with adjuvant qHPV vaccination efficacy estimated in terms of hazards of decreasing HSIL recurrence was $0 implying that additional data from a future study evaluating efficacy of adjuvant qHPV vaccination will not change our policy conclusion that “treatment plus vaccination” was cost-effective. Both the ICER and EVPI were sensitive to HSIL treatment compliance. Conclusion Post-treatment adjuvant qHPV vaccination in HIV-infected MSM aged 27 or above is likely to be cost-effective. Use of adjuvant qHPV vaccination could be considered as a potential strategy to reduce rising anal cancer burden among these high-risk individuals.
  • References (43)
  • Citations (8)
📖 Papers frequently viewed together
20173.27Vaccine
1 Citations
143 Citations
25 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References43
Newest
#1Ashish A. DeshmukhH-Index: 8
#2Elizabeth Y. ChiaoH-Index: 20
Last. Jagpreet ChhatwalH-Index: 23
view all 9 authors...
Background HIV-positive men who have sex with men (MSM) are at disproportionately high risk for anal cancer. There is no definitive approach for management of high-grade squamous intraepithelial lesions (HSIL), the anal cancer precursor, and evidence suggests that posttreatment adjuvant quadrivalent HPV (qHPV) vaccination improves HSIL treatment effectiveness. Our objective was to evaluate the optimal HSIL management strategy considering the clinical effectiveness and cost-effectiveness, and to ...
2 CitationsSource
#1Gregory R. Dion (NYU: New York University)H-Index: 7
#2Stephanie Erh Shuen Teng (NYU: New York University)H-Index: 4
Last. Ryan C. Branski (NYU: New York University)H-Index: 24
view all 8 authors...
Importance Human papillomavirus (HPV) vaccination is recommended for children and younger adults but not older adults or those with prior HPV exposure, leaving a large portion of the population at risk for HPV-mediated disease. Emerging data suggest a possible role for vaccination as an adjuvant treatment for individuals with HPV-related clinical disease. Objective To systematically review the literature regarding HPV vaccination for secondary disease prevention after treatment of active clinica...
8 CitationsSource
#1Gillian D Sanders (Duke University)H-Index: 43
#2Peter J. Neumann (Tufts Medical Center)H-Index: 81
Last. Theodore G. Ganjats (UM: University of Miami)H-Index: 58
view all 16 authors...
Importance Since publication of the report by the Panel on Cost-Effectiveness in Health and Medicine in 1996, researchers have advanced the methods of cost-effectiveness analysis, and policy makers have experimented with its application. The need to deliver health care efficiently and the importance of using analytic techniques to understand the clinical and economic consequences of strategies to improve health have increased in recent years. Objective To review the state of the field and provid...
489 CitationsSource
#1Cary P. Gross (Yale University)H-Index: 52
#2Ezekiel J. Emanuel (UPenn: University of Pennsylvania)H-Index: 81
4 CitationsSource
In the face of the growing cost of cancer care, the American Society of Clinical Oncology has published a proposed framework for assessing the value of cancer treatments, aiming to help physicians evaluate regimens on the basis of clinical benefit, toxicity, and cost.
44 CitationsSource
#1Ashish A. DeshmukhH-Index: 8
#2Jagpreet Chhatwal (Harvard University)H-Index: 23
Last. Scott B. CantorH-Index: 40
view all 6 authors...
Background. Recent evidence shows that quadrivalent human papillomavirus (qHPV) vaccination in men who have sex with men (MSM) who have a history of high-grade anal intraepithelial neoplasia (HGAIN) was associated with a 50% reduction in the risk of recurrent HGAIN. We evaluated the long-term clinical and economic outcomes of adding the qHPV vaccine to the treatment regimen for HGAIN in human immunodeficiency virus (HIV)–positive MSM aged ≥27 years. Methods. We constructed a Markov model based o...
25 CitationsSource
9 CitationsSource
#1Joaquin BurgosH-Index: 13
#2Adria CurranH-Index: 12
Last. Vicenç FalcóH-Index: 25
view all 10 authors...
18 CitationsSource
#1Ashish A. DeshmukhH-Index: 8
#2Elizabeth Y. Chiao (BCM: Baylor College of Medicine)H-Index: 20
Last. Scott B. CantorH-Index: 40
view all 4 authors...
Abstract We examined the long-term clinical and economic benefits of quadrivalent human papillomavirus (qHPV) vaccine as a secondary/adjunct prevention strategy in the prevention of recurrent high-grade intraepithelial neoplasia (HGAIN) in HIV-negative men who have sex with men (MSM) and are 27 years or older. We constructed a Markov model to evaluate the clinical effectiveness and cost-effectiveness of two strategies: (1) no qHPV vaccine after treatment for HGAIN versus (2) qHPV vaccine after t...
29 CitationsSource
BACKGROUND:High-grade dysplasia is the anal carcinoma precursor. Clinicians ablate high-grade dysplasia with laser, electrocautery, and infrared coagulation to prevent cancer.OBJECTIVE:The aim of this study was to determine the long-term effectiveness of high-grade dysplasia ablation and the inciden
50 CitationsSource
Cited By8
Newest
#1Helena C. Bartels (Mater Misericordiae University Hospital)H-Index: 1
#2James D. Postle (Mater Misericordiae University Hospital)H-Index: 1
Last. Donal J. Brennan (UCD: University College Dublin)H-Index: 32
view all 4 authors...
OBJECTIVE: The aim of this systematic review and meta-analysis was to review evidence supporting the use of prophylactic human papillomavirus (HPV) vaccines to influence the risk of recurrence of cervical intraepithelial neoplasia after surgical treatment. METHODS: A systematic literature search was performed for publications reporting risk of recurrence of cervical intraepithelial neoplasia after surgical treatment in patients receiving HPV vaccination (either in the prophylactic or adjuvant se...
Source
#1Ashish A. Deshmukh (University of Texas Health Science Center at Houston)H-Index: 8
#2Ryan Suk (University of Texas Health Science Center at Houston)H-Index: 2
Last. Keith Sigel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 14
view all 9 authors...
BACKGROUND: Squamous cell carcinoma of the anus (SCCA) incidence is rising in the United States (US). Study of incidence trends by stage at diagnosis, age-specific and birth cohort patterns, and trends in mortality could provide evidence for a true increase and etiological clues for this rise. METHODS: Using the US Cancer Statistics dataset, we examined trends in SCCA incidence (2001-2015) and mortality (2001-2016) rates. Joinpoint regression was used to compute annual and average annual percent...
10 CitationsSource
#1Clare Fiala (MSH: Mount Sinai Hospital, Toronto)H-Index: 5
#2Jennifer Taher (U of T: University of Toronto)H-Index: 7
Last. Eleftherios P. Diamandis (U of T: University of Toronto)H-Index: 99
view all 3 authors...
Background: The term P4 medicine (predictive, preventative, personalized, participatory) was coined by Dr. Leroy Hood of the Institute for Systems Biology to demonstrate his framework to detect and prevent disease through extensive biomarker testing, close monitoring, deep statistical analysis, and patient health coaching. Methods: In 2017, this group published the results of their “100 Person Wellness Project.” They performed whole genome sequencing and 218 clinical laboratory tests, measured 6...
1 CitationsSource
#1Marco J. Tomassi (KP: Kaiser Permanente)H-Index: 2
#2Maher A. AbbasH-Index: 12
Last. Daniel D. Klaristenfeld (KP: Kaiser Permanente)H-Index: 2
view all 3 authors...
Purpose To determine the impact of expectant management surveillance for patients at risk for squamous cell carcinoma of the anus (SCCA).
2 CitationsSource
#2Fabio ParazziniH-Index: 74
Last. Elmar A. Joura (Medical University of Vienna)H-Index: 25
view all 10 authors...
5 CitationsSource
#1Mireia DiazH-Index: 26
#2S de SanjoséH-Index: 74
Last. Laia BruniH-Index: 18
view all 4 authors...
Abstract Simulation models are commonly used to address important health policy issues that cannot be explored through experimental studies. These models are especially useful to determine a set of strategies that result in a good value for money (cost-effectiveness). Several mathematical models simulating the natural history of HPV and related diseases, especially cervical cancer, have been developed to calculate a relative effectiveness and cost-effectiveness of HPV vaccination and cervical ca...
3 CitationsSource
#1Massimo GiulianiH-Index: 23
#2Alessandra LatiniH-Index: 16
Last. Maria Gabriella DonàH-Index: 12
view all 12 authors...
Source
#1Ryan Suk (University of Texas Health Science Center at Houston)H-Index: 2
#2Parag MahaleH-Index: 11
Last. Ashish A. Deshmukh (University of Texas Health Science Center at Houston)H-Index: 8
view all 10 authors...
Importance In the last 4 decades, survival among patients with human papillomavirus (HPV)–associated cancers has improved, while the incidence of these cancers has increased among younger cohorts. Among survivors of HPV-associated cancers, persistent HPV infection may remain a risk factor for preventable HPV-associated second primary cancers (HPV-SPCs). Objectives To investigate the risk of HPV-SPCs among survivors of HPV-associated index cancers and to test the hypothesis that the HPV-SPC risk ...
2 CitationsSource
#1Didik Setiawan (UG: University of Groningen)H-Index: 3
#2Abrham Wondimu (UG: University of Groningen)
Last. Maarten Postma (UG: University of Groningen)H-Index: 44
view all 5 authors...
Background Men who have sex with men require special attention for human papillomavirus vaccination given elevated infection risks and the development of, in particular, anal cancer.
Source
#1Ashish A. Deshmukh (UF: University of Florida)H-Index: 8
#2Elizabeth Y. Chiao (BCM: Baylor College of Medicine)H-Index: 20
Last. Jagpreet Chhatwal (Harvard University)H-Index: 23
view all 9 authors...
Source